TruthArchive.ai - Related Video Feed

We are making this dream a reality with this announcement. The COVID vaccine has proven to be highly effective, although its logistics were complex due to the new technology.

Some batches of the vaccine may have serious side effects or be degraded. The batch number can be checked to see what to expect. Documentation shows that certain batches have more serious adverse effects. Even the best batches from Pfizer and Moderna had a high rate of serious adverse events in the short term, around 1800.

Vaccines are seen as magical but expectations should be tempered. Pfizer's vaccine is 95% effective, but efficacy drops over time. Boosters may be needed annually. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but we must adapt.

Pfizer did not disclose SV40 DNA in COVID vaccine to regulators, causing concern among Health Canada officials. The presence of SV40 DNA was confirmed by Pfizer but not shared with FDA, EMA, or HC initially. Despite claims that the DNA fragment is inactive and below regulatory limits, concerns remain about potential risks. Health Canada is working with international partners to address the issue for future vaccine strains. The focus seems to be on vaccine acceptance rather than addressing health risks associated with DNA contamination. Pfizer has not responded to requests for comment.

On October 6, 2021, I met with my manager, Conwell Gill, a principal scientist at Pfizer. We discussed the ethics of giving people experimental booster shots for money. mRNA vaccines have been around for 50 years but never made it to clinical use due to side effects. Pfizer and Moderna used the emergency of the pandemic to push through their vaccines. Pfizer collaborated with Beyond Tech on mRNA technology for COVID-19. Everything was new and rushed due to the pandemic. There was no time to think, only to act.

Pfizer imported its own batch of vaccines for the employee vaccination program, without testing by the TGA.

Medicines we know from the COVID vaccine. Very effective, very welcome. The logistics around that vaccine were not straightforward because of the new technologies. We're talking about countries here that do not have advanced

Pfizer imported its own batch of vaccine for the employee vaccination program, which was not tested by the TGA.

A group of European Parliament members wrote a letter to the European Medicines Agency (EMA) expressing concerns about the COVID-19 vaccines. The EMA responded, stating that the vaccines were only approved for individual immunization, not for controlling or preventing infections. They also emphasized the lack of data on preventing infections and even mentioned that exposure to the virus could increase the risk of infection, even in vaccinated individuals. The EMA highlighted the importance of carefully considering safety information before administering vaccines. The government's vaccination campaigns were deemed unauthorized and based on misinformation. The EMA's information undermines the vaccination policies of the Dutch government, and they should be held accountable for their actions.

Pfizer is not solely a German company; it has a partnership with Fosun Pharmaceutical, a major Chinese Communist Party-owned firm, to manufacture vaccines. Fosun has produced a billion doses, but China does not use them. BioNTech has transferred its technology to the Chinese government, raising concerns about the ownership of intellectual property related to the vaccines administered to millions of Americans. Storage instructions for the vaccines have been inconsistent, which could affect their stability and safety. The adult dosage for Moderna is 100 micrograms, while Pfizer's is 30 micrograms. Internal documents revealed that Pfizer had to abandon a higher dose due to safety concerns, yet this information wasn't communicated to those already vaccinated. Alarmingly, the CDC has now added these vaccines to the routine child vaccination schedule, with reports indicating that the dosage for children is being tripled.

The White House blames a few bad actors for spreading online misinformation that is causing harm. It is important to get vaccinated not only for personal protection but also to safeguard society. A member of the European Parliament from the Netherlands recently had a viral exchange with a Pfizer executive regarding whether the vaccine was tested for stopping virus transmission before being released. The executive clarified that the vaccines were extensively tested in clinical trials, but their specific effectiveness in stopping transmission was not known prior to market entry.

Thank you, Senator Canavan. Did Pfizer test if the COVID-19 vaccine could stop or reduce virus transmission before its late 2020 approval? To bring the vaccine to patients, we needed to show it was safe and effective in preventing illness, severe disease, and hospitalizations. The primary goal was to protect the vaccinated individual. I appreciate that, but my question remains unanswered. On December 3, 2020, your CEO stated that it was uncertain if vaccinated individuals could carry and spread the virus. Was he correct that Pfizer did not know if the vaccine could reduce transmission? We designed our clinical programs with regulatory agencies to demonstrate the vaccine's safety and effectiveness in preventing infections. Okay, let’s move on.

We have a surplus of vaccines and plan to donate a significant portion for COVID relief. Additionally, we are preparing for an annual vaccination program. Our goal is to assume that the entire population, starting from the age of twelve, will require two doses for complete vaccination on a yearly basis. We are currently focusing on procuring vaccines for this purpose.

I spoke with Pfizer's CEO, Albert Bourla, about the approval process. We discussed vaccine safety and serious side effects. Many companies and institutions are embracing the COVID vaccine due to its effectiveness. Logistics are crucial in this process. Translation (if needed): I talked to Pfizer's CEO, Albert Bourla, about the approval process. We talked about vaccine safety and serious side effects. Many companies and institutions are adopting the COVID vaccine because it works well. Logistics are important in this situation.

We negotiated with Pfizer for a deal to efficiently vaccinate a large portion of the Israeli population. We assured Pfizer that we would not share personal data but would monitor the vaccine's impact on disease levels, economy, and social life. We will track any effects on specific groups, like those with heart conditions, while respecting privacy.

I am currently not allowed to take the vaccine due to legal restrictions. There is a priority list for vaccination, and we are not permitted to participate in clinical trials as company employees. Our focus is on ensuring the functionality of our teams and the company as a whole. We are working towards finding a legal and fair solution to this situation, prioritizing the vaccination of our coworkers and partners.

Pfizer was asked if they tested whether their COVID-19 vaccine could reduce or stop the transmission of the virus before its approval. The Pfizer representative stated that the primary purpose of the vaccine was to protect the person who received it and prevent illness, severe disease, and hospitalizations. The senator then referred to a statement made by Pfizer's CEO on December 3, 2020, where he mentioned uncertainty about the vaccine's ability to reduce transmission. The Pfizer representative reiterated that their clinical programs were designed to demonstrate the vaccine's safety and effectiveness in preventing infections. Due to time constraints, the senator moved on without a definitive answer.

Speaker 0: Calvin will receive one shot. We are leading in global vaccination efforts with over 1.1 billion shots administered. We will continue our efforts and have provided significant funding to ensure everyone can be vaccinated. It is crucial for us to play the largest role in vaccinating the world.

In Davos, in January 2020, we had a conversation about a vaccine for COVID-19. At that time, COVID-19 wasn't a major concern, and we were focused on developing the vaccine.

Safe and effective vaccines have been developed and millions of doses are being delivered. The vaccines have been rigorously studied and proven to be safe and effective. Researchers have confirmed the safety and efficacy of various vaccines, including the Oxford AstraZeneca and Pfizer COVID-19 vaccines. Vaccination has been deemed safe and effective for children, with Pfizer's vaccine being 100% effective for kids aged 5 to 11. The European Medicines Agency has thoroughly assessed the vaccines and concluded they are safe and effective against COVID-19. The vaccines have undergone extensive testing and have been found to be extremely safe and effective. Overall, vaccines are considered safe, effective, and free.

We ensure there is enough capacity and competition for vaccines, leading to lower prices and the development of new vaccines. This includes vaccines for TB, malaria, HIV, and even COVID-19. To improve vaccines, we aim for longer duration and broader coverage, and plan to replace needles with patches. The pandemic has shown that we have not invested enough in these innovations. Our partners in India play a crucial role in achieving these breakthrough products.

Locking down entire populations and shutting down the economy were extreme measures taken to combat the pandemic. However, thanks to globalization, vaccines were developed in a record time of 9 months, compared to the usual 5 years. It is crucial to vaccinate globally to prevent the return of the virus in the form of new variants and increased contagion. Failure to do so will have negative consequences for us. Vaccination is not only important for recovery but also for anticipating future challenges.

Pfizer imported their own batch of vaccine specifically for the employee vaccination program, which was not tested by the TGA.

Pfizer is hesitant to distribute vaccines in certain countries due to liability issues. However, other vaccine manufacturers may be able to operate through subsidiaries and enter these countries. Our aim is to provide vaccines to developing nations based on their decisions. We have financing options available, but it is up to the countries to choose their systems and start procuring the vaccines.

We are discussing vaccine development in response to new variants and subvariants. Currently, we have the advantage of increased manufacturing capacity compared to 2020. Back then, we only produced 100,000 doses in a year, but now we are capable of producing much more to address the ongoing challenges posed by different strains of the virus.